{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:06:16Z","timestamp":1771434376010,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.urolonc.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:38:10Z","timestamp":1767011890000},"page":"110967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer-related genetic counseling in a safety-net healthcare setting"],"prefix":"10.1016","volume":"44","author":[{"given":"Prisca","family":"Mbonu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Mersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Heady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolonda C.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4443-6457","authenticated-orcid":false,"given":"Kalyani","family":"Narra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.urolonc.2025.12.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw110","article-title":"Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study","volume":"108","author":"Bratt","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.urolonc.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.19.02808","article-title":"Risk of prostate cancer associated with familial and hereditary cancer syndromes","volume":"38","author":"Beebe-Dimmer","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.003_bib0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/hmg\/dds425","article-title":"A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease","volume":"22","author":"Amin Al Olama","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.003_bib0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ng.91","article-title":"Multiple loci identified in a genome-wide association study of prostate cancer","volume":"40","author":"Thomas","year":"2008","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.urolonc.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pros.23795","article-title":"The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis","volume":"79","author":"Oh","year":"2019","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2025.12.003_bib0007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101927","article-title":"Hereditary prostate cancer - primetime for genetic testing?","volume":"81","author":"Heidegger","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.003_bib0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","article-title":"Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis","volume":"23","author":"Ryan","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_mmr carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database","volume":"67","author":"Moller","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0014","first-page":"63","article-title":"Detection of germline variants in patients with localized and metastatic prostate cancer through guideline-based testing","volume":"12","author":"Abusamra","year":"2025","journal-title":"Urol Pract"},{"issue":"22","key":"10.1016\/j.urolonc.2025.12.003_bib0015","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cam4.4778","article-title":"Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance","volume":"11","author":"Brady","year":"2022","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.urolonc.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/OP.20.00431","article-title":"Practical considerations and challenges for germline genetic testing in patients with prostate cancer: recommendations from the Germline Genetics Working Group of the PCCTC","volume":"16","author":"Szymaniak","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1464-410X.2010.09648.x","article-title":"Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study","volume":"107","author":"Mitra","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP inhibitors and prostate cancer: to infinity and beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.urolonc.2025.12.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21692","article-title":"Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations","volume":"3","author":"Schmid","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-023-04604-w","article-title":"Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?","volume":"93","author":"Catalano","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0023","unstructured":"National Comprehensive Cancer Network NCCN Clinical practice guidelines in oncology: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic (version 1.2025). Accessed November 17, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"issue":"17","key":"10.1016\/j.urolonc.2025.12.003_bib0024","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.18.02181","article-title":"Germline testing for men with prostate cancer: navigating an expanding new world of genetic evaluation for precision therapy and precision management","volume":"37","author":"Giri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.urolonc.2025.12.003_bib0025","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference","volume":"38","author":"Giri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.003_bib0026","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/JU.0000000000002865","article-title":"Satisfaction with clinician-led germline genetic counseling in patients with prostate cancer","volume":"208","author":"Abusamra","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.urology.2024.05.011","article-title":"Utilization of a third-party Partnership in Tele-genetic risk assessment program in Genitourinary oncology","volume":"191","author":"Lin","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0028","article-title":"TARGET: a randomized, noninferiority trial of a pretest, patient-driven genetic education webtool versus genetic counseling for prostate cancer germline testing","volume":"8","author":"Loeb","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/OP.23.00055","article-title":"Characterizing referrals for prostate cancer genetic services in a safety-net hospital","volume":"19","author":"Gunn","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0030","series-title":"Managed Care and the Future Viability of Safety Net Providers, Ein Lewin M, Altman S,editor. America\u2019s Health Care Safety Net: Intact but Endangered","year":"2000"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0031","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: prostate cancer. Accessed November 17, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"24","key":"10.1016\/j.urolonc.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.urolonc.2025.12.003_bib0033","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"10398","key":"10.1016\/j.urolonc.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.003_bib0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.14740\/wjon1896","article-title":"Patterns and frequency of pathogenic germline variants among prostate cancer patients utilizing multi-gene panel genetic testing","volume":"15","author":"Abu Hijlih","year":"2024","journal-title":"World J Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15490","article-title":"Changes in cancer screening in the US during the COVID-19 Pandemic","volume":"5","author":"Fedewa","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.003_bib0037","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s13187-023-02312-w","article-title":"Cancer screening and treatment delays during the COVID-19 pandemic and the role of health literacy in care re-engagement: findings from an NCI-designated Comprehensive Cancer Center sample","volume":"38","author":"Keim-Malpass","year":"2023","journal-title":"J Cancer Educ"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.003_bib0038","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jgc4.1792","article-title":"The impact of converting to telehealth for cancer genetic counseling and testing during the COVID-19 pandemic","volume":"33","author":"Proussaloglou","year":"2024","journal-title":"J Genet Couns"},{"key":"10.1016\/j.urolonc.2025.12.003_bib0039","article-title":"Understanding the uptake and challenges of genetic testing guidelines for prostate cancer patients","volume":"32","author":"Suri","year":"2022","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0040","article-title":"Germline variant spectrum among African American men undergoing prostate cancer germline testing: need for equity in genetic testing","volume":"6","author":"Giri","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1200\/OP.22.00634","article-title":"Racial differences in germline genetic testing for prostate cancer: a systematic review","volume":"19","author":"Briggs","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"16","key":"10.1016\/j.urolonc.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/cncr.33518","article-title":"Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer","volume":"127","author":"Quinn","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.003_bib0043","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.23228","article-title":"Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?","volume":"112","author":"Gross","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2025.12.003_bib0044","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jamcollsurg.2009.09.011","article-title":"Variations in referral patterns to high-volume centers for pancreatic cancer","volume":"209","author":"Chang","year":"2009","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44027","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs Health Care System","volume":"5","author":"Yamoah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2025.12.003_bib0046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euo.2021.07.006","article-title":"Prostate cancer racial disparities: a systematic review by the Prostate Cancer Foundation Panel","volume":"5","author":"Mahal","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.12.003_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.06.011","article-title":"Self-reported black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors","volume":"36","author":"Nettey","year":"2018","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.12.003_bib0048","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/pros.24123","article-title":"Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer","volume":"81","author":"Ledet","year":"2021","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.urolonc.2025.12.003_bib0049","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41391-022-00609-3","article-title":"Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine","volume":"26","author":"Marino","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.urolonc.2025.12.003_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41391-022-00517-6","article-title":"Germline alterations among Hispanic men with prostate cancer","volume":"25","author":"Pan","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:15:20Z","timestamp":1771431320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078143925004855"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.003","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer-related genetic counseling in a safety-net healthcare setting","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110967"}}